Table 5 Logistic regression analysis of the effect of novel anthropometric indicators on hyperuricemia.

From: The effects and predictive values of novel anthropometric parameters on uric acid levels and hyperuricemia in adults

Variables

 

Q1

Q2

Q3

Q4

OR (95% CI)

P

OR (95% CI)

P

OR (95% CI)

P

AIP

Male model a

1

1.16 (0.79–1.69)

0.457

1.54 (0.94–2.52)

0.089

2.00 (1.07–3.72)

0.029

CMI

1

1.61 (1.10–2.35)

0.015

1.77 (1.08–2.92)

0.024

1.59 (0.87–2.91)

0.133

LAP

1

1.80 (1.48–2.20)

< 0.001

2.74 (2.16–3.46)

< 0.001

4.96 (3.80–6.48)

< 0.001

VAI

1

0.71 (0.45–1.10)

0.123

0.48 (0.27–0.84)

0.011

0.47 (0.23–0.94)

0.034

TyG

1

1.64 (1.40–1.92)

< 0.001

2.77 (2.38–3.22)

< 0.001

3.98 (3.43–4.62)

< 0.001

ABSI

1

0.91 (0.79–1.05)

0.185

0.99 (0.86–1.14)

0.852

0.84 (0.73–0.98)

0.022

BRI

1

1.30 (1.12–1.51)

< 0.001

1.50 (1.29–1.75)

< 0.001

1.83 (1.57–2.13)

< 0.001

AIP

Male model b

1

1.10 (0.75–1.62)

0.636

1.41 (0.88–2.42)

0.138

1.82 (0.95–3.37)

0.071

CMI

1

1.72 (1.16–2.54)

0.007

1.84 (1.11–3.06)

0.019

1.69 (0.91–3.13)

0.094

LAP

1

1.75 (1.43–2.14)

< 0.001

2.60 (2.03–3.29)

< 0.001

4.58 (3.46–6.06)

< 0.001

VAI

1

0.70 (0.45–1.11)

0.128

0.50 (0.28–0.89)

0.019

0.53 (0.26–1.09)

0.082

TyG

1

1.62 (1.38–1.91)

< 0.001

2.83 (2.42–3.31)

< 0.001

4.65 (3.95–5.48)

< 0.001

ABSI

1

0.94 (0.81–1.08)

0.388

1.04 (0.90–1.21)

0.605

0.98 (0.84–1.15)

0.853

BRI

1

1.30 (1.12–1.52)

0.001

1.49 (1.28–1.75)

< 0.001

1.85 (1.57–2.19)

< 0.001

AIP

Female model a

1

0.95 (0.33–2.73)

0.919

1.02 (0.29–3.59)

0.979

1.14 (0.27–4.71)

0.861

CMI

1

1.49 (0.52–4.24)

0.455

3.59 (1.01–12.82)

0.049

5.57 (1.37–22.71)

0.017

LAP

1

2.02 (1.12–3.65)

0.019

4.20 (2.19–8.05)

< 0.001

7.85 (3.93–15.69)

< 0.001

VAI

1

0.64 (0.19–2.15)

0.475

0.35 (0.09–1.44)

0.145

0.33 (0.07–1.58)

0.164

TyG

1

1.58 (0.98–2.56)

0.060

3.11 (2.01–4.81)

< 0.001

7.38 (4.85–11.23)

< 0.001

ABSI

1

0.86 (0.62–1.20)

0.369

0.81 (0.58–1.13)

0.210

0.88 (0.63–1.22)

0.447

BRI

1

2.13 (1.36–3.34)

< 0.001

2.84 (1.82–4.42)

< 0.001

4.89 (3.14–7.63)

< 0.001

AIP

Female model b

1

1.10 (0.37–3.23)

0.869

1.35 (0.37–4.87)

0.651

1.63 (0.38–6.94)

0.507

CMI

1

1.21 (0.85–2.77)

0.717

2.37 (0.66–8.48)

0.188

3.47 (0.84–14.41)

0.086

LAP

1

1.54 (0.85–2.77)

0.153

2.49 (1.30–4.79)

0.006

3.62 (1.79–7.32)

< 0.001

VAI

1

0.72 (0.21–2.48)

0.601

0.47 (0.11-2.00)

0.306

0.45 (0.09–2.24)

0.326

TyG

1

1.35 (0.83–2.19)

0.228

2.52 (1.62–3.92)

< 0.001

5.52 (3.60–8.47)

< 0.001

ABSI

1

0.85 (0.61–1.19)

0.342

0.84 (0.60–1.17)

0.305

0.85 (0.60–1.19)

0.343

BRI

1

1.84 (1.17–2.90)

0.008

2.11 (1.34–3.33)

0.001

2.91 (1.82–4.66)

< 0.001

  1. Model a unadjusted; model b adjusted for age, SBP, DBP, FPG, smoking, alcohol consumption, exercise, and diet.
  2. AIP atherogenic index of plasma, CMI cardiometabolic index, LAP lipid accumulation product, VAI visceral adiposity index, TyG index triglyceride glucose index, ABSI A body shape index, BRI body roundness index.
Back to article page